US/UK/Canada

Share

Contacts

  • Roland Frösing

    Acting CEO


    +46 723 20 61 00
  • Torbjörn Sannerstedt

    Acting CFO


    +46 708 66 22 55

    • Links

    Quotes

    The fact that ChloraSolv, with very good efficacy, now can be used on venous leg ulcers and diabetic foot ulcers is very positive, not only for the patients and relatives but also for healthcare and society as this patient group is connected with large healthcare costs.
    Karin Fischer, CEO, RLS Global
    We are pleased to receive a positive confirmation from Lloyd’s register that ChloraSolv satisfies all required technological requirements.
    Karin Fischer, CEO of RLS Global
    RLS now has a detailed plan with activities for bringing ChloraSolv to the European markets in a structured manner.
    Karin Fischer, CEO
    Pick a time period -
    Tags ( Active)

    RLS Global ansöker om konkurs

    Styrelsen i RLS Global AB (publ) (”RLS” eller ”Bolaget”) har idag beslutat att ansöka om att försätta Bolaget i konkurs. Konkursansökan kommer att lämnas in idag den 20 november 2023 till Göteborgs Tingsrätt.Orsaken till konkursansökan är att RLS, trots intensivt arbete under 2023, inte har hittat en sund och fungerande lösning på sin ansträngda finansiella situation, på kort och medellång sikt. Styrelsen och ledningen har även under en längre tid arbetat hårt med målsättningen att utvidga de strategiska partnerskap som Bolaget behöver. Detta arbete har dessvärre under rådande

    RLS Global initiates strategic review process aiming to commercialize ChloraSolv

    The RLS Global Board of Directors has resolved to initiate a strategic review process to enable the commercial roll out of ChloraSolv across European markets.RLS Global announced earlier today that RLS Global and Convatec have agreed to terminate the collaboration agreement. RLS Global and Convatec have agreed that both parties will work jointly and with the common target to have a smooth handover from Convatec to RLS Global.   The RLS Global Board of Directors will consider all strategic options, including a partnership, a sale of the company, a sale of ChloraSolv, or a financial

    RLS Global and Convatec have agreed to terminate collaboration agreement

    RLS Global and Convatec have mutually agreed to terminate their collaboration agreement for ChloraSolv in European markets. The commercial rights to ChloraSolv will be returned to RLS Global.On June 17th 2021, RLS Global and Convatec entered a collaboration agreement for the commercialization of ChloraSolv in most European markets, with additional rights for Convatec to opt in to commercialize in further global markets. Since then, Convatec has launched ChloraSolv in the UK market and continued sales efforts in the Swedish market. Convatec recognizes the importance of debridement and the

    First patient included in new clinical investigation on pressure ulcers

    RLS Global’s new clinical investigation with ChloraSolv for the treatment of pressure ulcers includes six clinics in Sweden, Finland and the UK. The first patient was enrolled on September 1 at a clinic in the UK.The investigation has been approved by authorities in all three countries.Pressure ulcers belong to the group of hard-to-heal wounds and cause much suffering and high costs worldwide. Studies show that pressure ulcers affect as many as over 10 (6–27) percent of all hospitalised patients in Europe (ref). Previous investigations have shown that ChloraSolv is effective and safe in

    ChloraSolv recommended for UK CA certification required for UK market after Brexit

    As a result of Brexit, a so-called UK CA certification will be required for medical devices placed on the market in Great Britain. Today, a positive recommendation for UK CA certification has been provided for RLS Global’s wound debridement product ChloraSolv.“RLS Global has now secured a long-term regulatory compliance, and hence, access to the UK market for ChloraSolv”, says Roland Frösing, acting CEO, RLS Global. RLS Global is now awaiting the formal UK CA certificate.      THIS IS CHLORASOLVChloraSolv is a debriding gel, based on a unique hypochlorite technology, which is

    RLS GLOBAL AB (publ) PUBLISHES INTERIM REPORT FOR THE PERIOD APRIL–JUNE 2023

    RLS Global AB (publ) (“RLS”) or the “Company”) today publishes the Company’s interim report for the second quarter 2023.APRIL 1st – JUNE 30th (Previous year in brackets) · Net sales amounted to TSEK 223 (TSEK 397) · Earnings before interest and taxes (EBIT) amounted to MSEK -7,5 (MSEK 5,8) · Earnings per share before dilution at SEK -0,09 (SEK 0,09) · Cash flow from operating activities amounted to TSEK -6 904 (TSEK -5 929) · Liquid assets at the end of the period MSEK 4,6 ( MSEK 5,8) · Equity ratio was 71 % (43 %)   JANUARY 1st – JUNE 30th (Previous year in

    RLS Global appoints Torbjörn Sannerstedt as new Chief Financial Officer

    RLS Global AB (publ) today announces that Torbjörn Sannerstedt has been appointed new Chief Financial Officer (CFO). Torbjörn succeeds RLS Global's outgoing CFO, Eva Jagenheim.Torbjörn Sannerstedt holds an MBA and has extensive experience from positions as CFO in companies such as AcadeMedia AB, Navamedic ASA and Halmstad Energi och Miljö AB. He has also been CEO of LMI Selcom AB and administrative manager of Kinnasand AB. Torbjörn Sannerstedt will perform his assignment for RLS Global on a consultancy basis through the company Business Control Partner Norden AB in Göteborg."I am pleased

    RLS Global AB (publ) Interim Report, Q1, 2023

    JANUARY 1st – MARCH 31st (Previous year in brackets) · Net sales amounted to TSEK 89 (TSEK 305) · Earnings before interest and taxes (EBIT) amounted to MSEK -7,5 (MSEK -5,3) · Earnings per share after dilution at SEK -0,09 (SEK 0,07) · Cash flow from operating activities amounted to TSEK -7 084 (TSEK -6 730) · Liquid assets at the end of the period MSEK 13,4 (MSEK 4,7) · Equity ratio was 82 % (77 %)    Summary of events during FIRST quarter · An extra AGM was held 9 February. · Lars Johansson was elected Board Member and Chairman of the Board at the extra

    ChloraSolv shows notably greater antibiofilm activity in vitro compared to other debridement products in published article

    A recently published article in Wounds UK concludes that ChloraSolv wound debridement gel shows notably greater antibiofilm activity in vitro, compared to other debridement products and techniques, thus highlighting the promise for ChloraSolv which combines softening of devitalised tissue with antibiofilm activity.The peer-reviewed article “The in vitro antibiofilm performance of ChloraSolv® Wound Debridement Gel” (authors Dr Daniel Metcalf, Dr Kate Meredith and Susanne Olausson) was recently published in the journal Wounds UK, Vol 19, No 1, 2023. The article is available here 

    RLS Global AB (publ) Year-end Report, Q4, 2022

    OCTOBER 1st – DECEMBER 31st (previous year in brackets) · Net sales amounted to TSEK 291 (TSEK 219) · Earnings before interest and taxes (EBIT) amounted to MSEK -7,9 (MSEK -7,8) · Earnings per share after dilution at SEK -0,10 (SEK 0,09) · Cash flow from operating activities amounted to TSEK -5 779 (TSEK -4 887) · Liquid assets at the end of the period MSEK 20,5 ( MSEK 11,5) · Equity ratio was 83 % (75 %)  JANUARY 1st – DECEMBER 31st (previous year in brackets) · Net sales amounted to TSEK 1 198 (TSEK 653) · Earnings before interest and taxes (EBIT) amounted

    Lars Johansson nominated as new Chairman of the Board of RLS Global AB

    RLS Global AB announces today that Lars Johansson is nominated for election as new Chairman of the Board. Current Chairman Steve Krognes will step down and the change of Chairman is planned for an upcoming extraordinary general shareholder meeting.Lars Johansson is an experienced Managing Director and board professional from the medical device and pharmaceutical industries. He brings significant leadership experience both from Sweden and internationally, and has worked at Johnson & Johnson for close to three decades in positions of increasing seniority and impact. His most recent previous

    RLS Global: The rights issue is registered and the trading in Paid Subscription Shares ceases

    RLS Global AB (publ) (”RLS Global” or "the Company”) has completed a rights issue of shares that closed on 11 November, 2022. The rights issue is now registered with the Swedish Companies Registration Office and the last day for trading in paid subscribed shares ("BTA") will be Wednesday, December 14th, 2022. The record date will be December 16th, 2022, after which the BTAs are converted into ordinary shares on Tuesday December 20th, 2022.The information was submitted for publication, through the agency of the contact persons set out below, on December 9[th], 09.00 CEST.

    RLS Global AB (publ) Interim Report, Q3, 2022

    JULY 1st – SEPTEMBER 30th (Previous year in brackets) · Net sales amounted to TSEK 198 (TSEK 132). · Earnings before interest and taxes (EBIT) amounted to MSEK -5,2 (MSEK 6,2). · Earnings per share after dilution at SEK -0,07 (SEK 0,09). · Cash flow from operating activities amounted to TSEK -5 114 (TSEK -6 214). · Liquid assets at the end of the period MSEK 3,7 (MSEK 16,4). · Equity ratio was 77 % (86 %).   JANUARY 1st–SEPTEMBER 30th (Previous year in brackets) · Net sales amounted to TSEK 904 (TSEK 472). · Earnings before interest and taxes (EBIT)

    RLS Global: Outcome in RLS Global’s rights issue

    NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO RUSSIA, BELARUS, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, UNITED STATES OF AMERICA OR ANY OTHER JURISDICTION WHERE SUCH ACTION IS IN WHOLE OR IN PART FOR LEGAL RESTRICTIONS. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER TO ACQUIRE SECURITIES IN RLS GLOBAL AB. SEE THE "IMPORTANT INFORMATION" SECTION BELOW.RLS Global AB (publ) (”RLS Global” or the “Company”) today announces the outcome of the rights issue with preferential rights for the shareholders (the “Rights

    RLS Global’s CEO Björn Larsson interviewed by Erik Penser Bank about the ongoing rights issue

    Erik Penser Bank has today published a video-recorded interview with Björn Larsson, CEO, RLS Global AB. The reason for the CEO interview is to provide all shareholders and stakeholders with information in connection with RLS Global AB’s ongoing rights issue.The interview is uploaded on Erik Penser Bank’s YouTube channel and can be viewed through the following link. The interview is approximately 10 minutes long. Click to see interview. 

    RLS Global: RLS Global publishes prospectus

    RLS Global AB (publ) (”RLS Global” or the “Company”) today announces that the Swedish Financial Supervisory Authority (the “SFSA”, sw. Finansinspektionen) has approved the prospectus that RLS Global has prepared due to the upcoming rights issue. The prospectus is available at RLS Global’s website (www.rls.global) and Erik Penser Bank's website (www.penser.se).Prospectus The prospectus that RLS Global has prepared due to the upcoming rights issue has today been approved and registered by the SFSA. The prospectus, containing complete terms and instructions, and application forms can be

    RLS Global: RLS Global resolves on a fully guaranteed rights issue of approximately SEK 29.4 million

    NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO RUSSIA, BELARUS, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, UNITED STATES OF AMERICA OR ANY OTHER JURISDICTION WHERE SUCH ACTION IS IN WHOLE OR IN PART FOR LEGAL RESTRICTIONS. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER TO ACQUIRE SECURITIES IN RLS GLOBAL AB. SEE THE "IMPORTANT INFORMATION" SECTION BELOW.The board of directors of RLS Global AB (publ) (the "Company" or "RLS Global") has today, pursuant to the authorization granted by the annual general meeting on

    RLS Global carries out an issue of shares by way of set-off, totalling approximately SEK 10

    The board of directors of RLS Global AB (publ) (the “Company” or “RLS Global”) has today, pursuant to the authorization granted by the annual general meeting on 19 May 2022, resolved on a directed issue of new shares, totalling approximately SEK 10 million (the “Issue”), to one of the Company’s principal shareholders, i.e., Zebra Holding and Investments (Guernsey) Limited (“Zebra”). The subscription price is approximately SEK 2.987 per share. The issue fund has been paid by set-off of the remaining loan, in a total of approximately SEK 10 million in claim that Zebra had against the Company.

    RLS GLOBAL AB (PUBL) INTERIM REPORT, Q2, 2022

    APRIL 1[st] – JUNE 30[th ](Previous year in brackets) · Net sales amounted to TSEK 397 (TSEK 244). · Earnings before interest and taxes (EBIT) amounted to MSEK -5,8 (MSEK 8,5). · Earning per share before dilution at SEK -0,09 (SEK 0,13). · Cash flow from operating activities amounted to TSEK -5 929 (TSEK -6 280). · Liquid assets at the end of the period MSEK 5,8 (MSEK 6,9). · Equity ratio was 43 % (87 %).  JANUARY 1[st] – JUNE 30[th ](Previous year in brackets) · Net sales amounted to TSEK 705 (TSEK 302). · Earnings before interest and taxes (EBIT) amounted

    Björn Larsson new CEO of RLS Global

    The Board of Directors of RLS Global AB (publ) has today appointed Björn Larsson as new CEO. Björn Larsson, who joins the company from Observe Medical ASA, will assume the role of CEO on 1 October.Björn Larsson has solid experience from the global medical device and pharmaceutical industry where he has held various positions in companies such as ABIGO Medical AB and AstraZeneca.“I look forward to leading the company into the next phase and, together with the board and the team, realizing the potential of RLS' unique, patented hypochlorite platform, ChloraSolv. With my experience in the

    New case reports of ChloraSolv presented in Journal of Wound Care supplement

    During the last six months, RLS Global and ConvaTec have worked in close collaboration to collect clinical experiences of ChloraSolv from three different wound centers in the UK. Six case studies have been compiled into a report and published as a supplement in Journal of Wound Care, issue no 7 2022 . The aim is to demonstrate the implementation of ChloraSolv in practice.The clinical experience shows that ChloraSolv has strong debridement efficacy, as well as good safety and ease of use. It means that the technology can be used by any

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe